Cabozantinib, a c-MET and VEGFR2 inhibitor, was tested in a Phase I study, combined with TMZ during the Stupp protocol [328] and in two Phase II studies as monotherapy in recurrent GBM (NCT01068782 and NCT00704288). The gene discussed is MET; the disease is glioblastoma.